Empowering clinicians with technologies that solve real challenges.
About Us
Keya Medical is dedicated to the development and commercialization of deep learning-based medical devices for disease diagnosis and treatment with a goal to revolutionize the medical device industry.
Keya Medical’s team of 407 employees combines expertise in deep learning, computer vision, medical image processing, fluid dynamics, and medical robotics. Many of our research and development team members previously worked at world-renowned medical device companies and were deeply involved in the successful development of leading medical devices. Our multidisciplinary expertise allows us to provide solutions that address the most pressing challenges facing clinicians today.
Keya Medical has developed solutions for specialties including cardiology, neurology, radiology, pathology, and surgery. We are proud to collaborate with 728 hospitals to bring solutions to clinical use that improve diagnostics, care processes, and clinical outcomes.
By the Numbers
Employees
Collaboration Partners
Registered Patents
Milestones
2016
January
Keya Medical is founded
2017
October
Keya Medical establishes the first AI diagnostic laboratory in China
2018
DeepVessel FFR enters the CFDA Special Approval Channel for Innovative Medical Devices
June
Keya Medical receives ISO 13485 certification
August
DeepVessel FFR receives CE Mark
2019
December
Keya Medical is selected to the Top 100 Medical Companies of the Future list by VCBeat Research
2020
DeepVessel FFR becomes the first Class-III AI medical device approved for clinical use by the Chinese National Medical Products Administration
February
Keya Medical raises over $15 million in strategic funding
March
CuraRad-ICH receives U.S. FDA 510(k) clearance
August
Keya Medical closes $20 million in Series B+ funding
September
Keya Medical is awarded China’s Most Promising Company Award by Ernst & Young Fudan China
CuraRad-ICH joins Nuance AI Marketplace for Diagnostic Imaging
November
Keya Medical closes $30 million in Series C funding
December
Keya Medical raises $46 million in Series D funding
2021
DeepVessel FFR demonstrates an accuracy of 92% in a single-center retrospective study conducted by researchers at Fuwai Hospital
February
Keya Medical’s President of R&D, Dr. Kunlin Cao, is recognized on the 2021 Forbes China Up-and-Coming Businesswomen list
Researchers at the First Affiliated Hospital of Jinan University conduct a single-centered retrospective study on DVFFR
2022
April
DeepVessel FFR received FDA clearance
Industry Recognition
Keya Medical is a leading medical technology company with triple certification of China NMPA, EU CE, and US FDA
NMPA
January 2020
DeepVessel® FFR
CE
August 2018
DeepVessel® FFR
FDA
April 2020
CuraRad® ICH
April 2022
DeepVessel® FFR
Keya Medical wins the Frontier Technology Award at the China Medical Equipment Fair (CMEF) 2021
Keya Medical is ranked sixth on the Top 100 Medical Companies of the Future List by VCBeat Research
Dr. Kunlin Cao is named to the 2021 Forbes China Up-and-Coming Businesswomen List
Keya Medical wins the 2020 Most Growth Enterprise Award at the New Economy Industry Annual Summit Awards Ceremony hosted by iiMedia Research
Keya Medical is selected as one of the top 50 Global Healthcare Technology Companies at World Innovators Meet (WIM) 2020
Keya Medical wins the 2020 Ernst and Young Fudan China’s Most Promising Company Award
Keya Medical wins the 2020 China Health Industry Award for “Intelligent Medical Innovative Enterprise”
Products
DeepVessel FFR
CuraRad-ICH
Solutions
All Solutions
Diagnostic Solutions
Treatment Solutions
Solution Suites
